JITC Digest November 2020

jitc-logo.gif

Inside this Issue:

Letter from the Editor

Dear JITC Readers,pedro-romero_1__1_.jpg

I hope you enjoy this latest edition of the JITC digest. You are receiving this email after the conclusion of SITC’s 35th anniversary Annual Meeting and Pre-Conference Programs, this year re-imagined as an entirely virtual experience. Although we sorely missed the opportunity to interact with our colleagues in person, the virtual platform was an amazing opportunity for participants from around the world to experience the latest and greatest in immunotherapy research. Hopefully, you had an opportunity to stop by the virtual JITC booth during the meeting!

Included within the highlights of the meeting was the presentation of the annual JITC best paper awards. This year, the manuscripts honored were, “CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma” and “Mechanisms regulating PD-L1 expression on tumor and immune cells.” Of course, the award selection was a difficult decision this year, as JITC is blessed with an abundance of excellent papers, which is truly a “problem” that the journal is lucky to have as we continue to grow and expand.

Among the many important manuscripts published this month is “The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia,” which is sure to be a valuable resource for the hematology-oncology community.

The rest of the papers in this month’s JITC digest touch on some hot topic areas in immunotherapy—myeloid cells, metabolism and novel targets, among others—inching the field forward to the overall goal of identifying and expanding the population of patients who may benefit, while revealing new insights into the mechanisms of actions of some familiar agents.

Hongfei Wang et al look beyond the traditional T cell-centered view for immuno-oncology and developed a novel myeloid-targeting agent that showed robust synergy with radiation in mouse models.
Blood-based biomarkers for response to checkpoint blockade have long been elusive, but Alissa Keegan and colleagues make use of ultrasensitive single-molecule array technology to identify a familiar cytokine—IL-6—as a potential factor with predictive value for survival benefit after PD-1 blockade.

New nuance in the T cell physiology associated with checkpoint blockade efficacy is provided by Hannah S Newton et al, who perform elegant electrophysiology experiments to identify distinct differences in voltage-gated ion channel activity, calcium flux and chemotaxis in blood- and tumor-infiltrating lymphocytes among patients with pembrolizumab-responsive and non-responsive head and neck cancers.

Potential utility for PI3Kdelta inhibition beyond hematologic malignancies and in solid tumors is demonstrated by Sarah Nicol Lauder and colleagues—intriguingly, they show that combination with anti-LAG3 therapy leads to even more pronounced effects, highlighting the promise of combinatorial approaches for novel immunotherapy targets.

Finally, do not miss an exceptional review by Maria Zagorulya, Ellen Duong and Stefani Spranger, discussing the implications of tissue-specific variability in myeloid cells on the efficacy of checkpoint blockade therapy.

Warm regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer


JITC Editor Picks

CD47/SIRPalpha blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

Hongfei Wang, Yixuan Sun, Xiuman Zhou, Chunxia Chen, Ling Jiao, Wanqiong Li, Shanshan Gou, Yanying Li, Jiangfeng Du, Guanyu Chen, Wenjie Zhai, Yahong Wu, Yuanming Qi, Yanfeng Gao
Journal for ImmunoTherapy of Cancer 2020;8:e000905 (5 October 2020)
Research

Summary:

Tumor cells express the ‘don't eat me’ signal CD47 on their surfaces, which suppresses phagocytosis by macrophages through interaction with SIRPalpha. Previous efforts at targeting CD47 with monoclonal antibodies have been associated with profound anemia, as the receptor is also found on hematopoietic stem and progenitor cells. Reasoning that a small peptide-based therapeutic could sidestep some systemic toxicity and enhance tumor penetration, Hongfei Wang et al performed five rounds of phage-display biopanning to identify a short fragment that specifically bound CD47 and blocked interaction with SIRPalpha. The lead candidate as validated by in vitro binding assays, pep-20, was shown to enhance macrophage-mediated phagocytosis of three different human tumor cell lines (MCF7, HT29 and Jurkat) in culture. In two mouse models of colon cancer (MC38 and CT26), peritumoral pep-20 subcutaneous injection slowed tumor growth and prolonged survival with no significant toxicity. Notably, intratumoral CD8+ T cell populations, as well as interferon gamma expressing CD8+ T cells were significantly increased in tumor-draining lymph nodes and spleen after treatment with pep-20. Depletion of macrophages eliminated anti-tumor activity of pep-20. A docking model was generated in silico, which led to the development of a D-amino acid-subsituted isomer, pep-20-D12. Unlike the parent peptide, which only showed anti-tumor activity with local administration, pep-20-D12 demonstrated significant slowing of tumor progression when administered systemically. Notably, when given in combination with radiotherapy, pep-20-D12 led to significant delay and sometimes complete regression of tumor growth. Most surprisingly, perhaps, phagocytosis of malignant cells was demonstrated by tumor infiltrating monocytic myeloid-derived suppressor cells after radiotherapy with pep-20-D12. The peptide may be a promising candidate for further development, emphasizing the future potential for targeting the myeloid compartment for immunotherapy.

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Alissa Keegan, Biagio Ricciuti, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mariano Severgnini, Mark M Awad, David R Walt
Journal for ImmunoTherapy of Cancer 2020;8:e000678  (5 October 2020)

Research

Summary:

No blood-based biomarkers reliably predict efficacy of immune checkpoint blockade for solid tumors. Hypothesizing that changes in systemic cytokine levels with initial doses of anti-PD-(L)1 therapy may correlate with clinical responses, Alissa Keegan and colleagues took advantage of new ultrasensitive single-molecule array (Simoa) technology to measure protein levels down to attomolar concentrations, in two cohorts of patients with non-small cell lung cancer that received anti-PD-(L)1 immunotherapy. In the first cohort of 47 patients (33 treated with pembrolizumab, 10 with nivolumab, and 4 with other agents), a decrease of serum IL-6 levels of 40% or more on treatment was associated with longer progression-free survival (PFS). On-treatment IL-6 levels ranged from 0.60 to 78? pg/mL, and the quartile with the lowest levels tended to have longer PFS. In more detail, the 11 patients with reduced IL-6 after checkpoint blockade had a median PFS of 11 months (95%? CI 4.2 to not reached), whereas those with stable (n=21) or increased IL-6 (n=15) had median PFS of 5 months (95%? CI 3.4 to not reached) and 4 months (95%? CI 2.3 to not reached), respectively. Although IL-6 change did not retain a significant association with PFS in a multivariate model after adjusting for age, performance status, PD-L1 and TMB, the sample size was small and, neither did the known prognostic factors PD-L1 and TMB. In a second cohort where 10 additional ultrasensitive Simoa plasma cytokine assays were performed, IL-6 percentage decrease was not statistically associated with PFS with immunotherapy (n=25) or chemoimmunotherapy (n=16), although a trend toward significance was observed. A significant association between IL-6 levels and C-reactive protein levels was seen in this second cohort. None of five other known inflammatory cytokines (IL-10, CXCL10, IL-17A, IL-15, and IL-1-beta) demonstrated statistically significant association with clinical responses. This study lays the groundwork for further development of blood-cytokine level-based biomarkers for response to checkpoint blockade, pending validation in larger cohorts with greater statistical power as well as in additional disease settings.

PD-1 blockade enhances K+ channel activity, Ca2+ signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer

Hannah S Newton, Vaibhavkumar S Gawali, Ameet A Chimote, Maria A Lehn, Sarah M Palackdharry, Benjamin H Hinrichs, Roman Jandarov, David Hildeman, Edith M Janssen, Trisha M Wise-Draper, Laura Conforti
Journal for ImmunoTherapy of Cancer 2020;8:e000844 (14 October 2020)
Research

Summary:

Ion channels are integral to almost all aspects of cytotoxic T cell anti-tumor functions including migration, proliferation, and cytokine production. Hypothesizing that ion channels may also play a role in mechanisms of resistance to immunotherapies targeting the PD-(L)1 axis, Hannah S Newton et al performed a series of sophisticated electrophysiology experiments on tumor-infiltrating lymphocytes (TILs) isolated from samples from immunotherapy-experienced and immunotherapy-naïve cohorts of patients with squamous cell carcinoma of the head and neck (HNSCC). Of the two voltage-gated ion channels that are critical for T cell effector function, pembrolizumab treatment was not associated with any difference in TIL KCa3.1 activity; however, Kv1.3 activity in CD8+ TILs was higher in samples from patients who were treated with pembrolizumab—independent of expression levels—and the increase in Kv1.3 activity was more pronounced for responsive disease (72% versus 180%). In circulating T cells, pembrolizumab treatment was associated with immediate initial increases in KCa3.1 activity for all patients. Patients with responsive disease, however, showed a sustained increase of Kv1.3 activity. Long-lasting increases in calcium fluxing were also observed in peripheral blood T cells from patients with responsive disease after pembrolizumab treatment, which accompanied increased interferon gamma production in this cohort. Intriguingly, while T cells from patients with pembrolizumab-non-responsive disease showed significant mobility defects in the presence of adensosine, chemotaxis was not inhibited by adenosine for peripheral blood T cells from patients with pembrolizumab-responsive disease—similar to what was seen with cells from healthy donors. The findings for the first time reveal a critical contribution of ion channels in response to checkpoint blockade.

Enhanced antitumor immunity through sequential targeting of PI3Kdelta and LAG3

Sarah Nicol Lauder, Kathryn Smart, Veerle Kersemans, Danny Allen, Jake Scott, Ana Pires, Stefan Milutinovic, Michelle Somerville, Sean Smart, Paul Kinchesh, Elena Lopez-Guadamillas, Ellyn Hughes, Emma Jones, Martin Scurr, Andrew Godkin, Lori S Friedman, Bart Vanhaesebroeck, Awen Gallimore
Journal for ImmunoTherapy of Cancer 2020;8:e000693 (22 October 2020)

Research

Summary:

PI3Kdelta inhibition is already used in the treatment of hematologic malignancies, and recent studies demonstrate that targeting PI3Kdelta may further promote antitumor immunity for solid cancers by dampening regulatory T cells (Tregs). Sarah Nicol Lauder and colleagues thoroughly characterize the mechanisms by which PI3Kdelta inhibition may enhance antitumor immunity, through effects on both effector T cells and Tregs, and further demonstrate potential synergy with LAG3 inhibition for enhanced cancer control. In mouse models of triple negative breast cancer (4T1 tumors), PI3Kdelta inhibitor monotherapy leads to attenuated tumor growth rates in all treated animals, but regression of malignant masses was only seen in roughly 12.5% of animals. Phenotypic analysis of effector T cells from regressing tumors after PI3Kdelta inhibition showed significant expansions of gp70 antigen-reactive CD8+ tumor infilitrating lymphocytes (TILs), increased TCF1+ CD4+ TILs, and a relative lack of expression of CD69 on CD8+ TILs compared to in non-regressing tumors. Furthermore, Glut1 expression was clearly higher on CD8+ T cells isolated from regressor tumors after PI3Kdelta inhibition, as was mitochondrial membrane potential in tumor-infiltrating CD4+ and CD8+ T cells compared with control mice. In non-regressing tumors after PI3Kdelta inhibition, the proportion of Tregs expressing LAG3 as well as CD69 were both higher, and proliferation, measured by Ki67 staining, was enhanced compared to in regressing tumors. Treatment with anti-CD69 blocking antibodies, either alone or in combination with PI3Kdelta inhibition had no effect on tumor growth. However, anti-LAG3 in combination with PI3Kdelta inhibition resulted in significantly greater tumor control than either monotherapy, leading to regression in 50% of the mice treated with the dual regimen. Studies in MC38 and CT26 colon cancer cell lines showed similar synergy. The results support further study of PI3Kdelta inhibition combined with LAG3 as a strategy to enhance efficacy for checkpoint blockade beyond the PD-(L)1 axis.

Impact of anatomic site on antigen-presenting cells in cancer

Maria Zagorulya, Ellen Duong, Stefani Spranger
Journal for ImmunoTherapy of Cancer 2020;8:e001204 (5 October 2020)

Review

Summary:

Checkpoint blockade therapy achieves exceptional results against some malignant melanomas, lung, and kidney carcinomas, yet the fraction of patients who derive benefit from these therapies for several other malignancies, including pancreatic cancer and ovarian cancer is disappointingly low. Additionally, metastatic lesions to the liver respond very poorly to checkpoint blockade. Because myeloid cells are known to shape anti-tumor T cell responses, Maria Zagorulya, Ellen Duong and Stefani Spranger review the tissue-resident myeloid antigen-presenting cells (APCs) in different tumor types, with an emphasis on the contribution of dendritic cells (DCs) to disease control. Adding nuance to the traditional view of the cancer-immunity cycle, in which myeloid APCs provide the key initiating stimulus to initiate anti-tumor T cell responses, the review provides evidence that prevalence and characteristics of distinct DC subsets within the tumor microenvironment—especially conventional type 1 DCs (cDC1s)—varies substantially between checkpoint blockade-responsive and non-responsive tumors. The review establishes a framework to consider myeloid-targeted modulatory strategies to stimulate DCs residing at different organ sites.

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab

Yutaka Natori, Eisaku Sasaki, Shu Soeda, Shigenori Furukawa, Yusuke Azami, Emi Tokuda, Takashi Kanbayashi, Shigehira Saji
Journal for ImmunoTherapy of Cancer 
2020;8:e001164 (1 October 2020)
Case Report

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer

Claire F Friedman, Alexandra Snyder Charen, Qin Zhou, Michael A Carducci, Alexandre Buckley De Meritens, Bradley R Corr, Siqing Fu, Travis J Hollmann, Alexia Iasonos, Jason A Konner, Panagiotis A Konstantinopoulos, Susan C Modesitt, Elad Sharon, Carol Aghajanian, Dmitriy Zamarin
Journal for ImmunoTherapy of Cancer 
2020;8:e001126 (1 October 2020)
Research

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Jared M Weiss, Taofeek K Owonikoko, Julie A Rytlewski, Jill Hood, Zhao Yang, Rajesh K Malik, Jay C Strum, Patrick J Roberts
Journal for ImmunoTherapy of Cancer 
2020;8:e000847 (1 October 2020)
Research

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

Claudia Parisi, Giuseppe Lamberti, Maurizio Zompatori, Francesco Gelsomino, Stefania Salvagni, Francesca Sperandi, Andrea Ardizzoni
Journal for ImmunoTherapy of Cancer 2020;8:e000502  (1 October 2020)
Case Report

Regulation of tumor growth by leukocyte-specific protein 1 in T cells

Riri Kwon, Bong-Ki Hong, Kang-Gu Lee, Eunbyeol Choi, Laurent Sabbagh, Chul-Soo Cho, Naeun Lee, Wan-Uk Kim
Journal for ImmunoTherapy of Cancer 2020;8:e001180  (5 October 2020)
Research

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab

Jamie S Lin, Daniel Y Wang, Omar Mamlouk, William F Glass, Maen Abdelrahim, Cassian Yee, Ala Abudayyeh
Journal for ImmunoTherapy of Cancer 2020;8:e001287  (5 October 2020)
Case Report

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

Shang-Jui Wang, Karishma Khullar, Sinae Kim, Nikhil Yegya-Raman, Jyoti Malhotra, Roman Groisberg, Samuel H Crayton, Ann W Silk, John L Nosher, Michael A Gentile, Janice M Mehnert, Salma K Jabbour
Journal for ImmunoTherapy of Cancer 2020;8:e000889  (5 October 2020)
Research

89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

Elly L van der Veen, Danique Giesen, Linda Pot-de Jong, Annelies Jorritsma-Smit, Elisabeth G E De Vries, Marjolijn N Lub-de Hooge
Journal for ImmunoTherapy of Cancer 
2020;8:e000938 (5 October 2020)
Research

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity

Karla A Lee, Heather Shaw, Véronique Bataille, Paul Nathan
Journal for ImmunoTherapy of Cancer 2020;8:e000577  (5 October 2020)
Commentary

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

Natalia Rodrigues Mantuano, Marina Natoli, Alfred Zippelius, Heinz Läubli
Journal for ImmunoTherapy of Cancer 2020;8:e001222  (5 October 2020)
Review

T-cell agonists in cancer immunotherapy

Yeonjoo Choi, Yaoyao Shi, Cara L Haymaker, Aung Naing, Gennaro Ciliberto, Joud Hajjar
Journal for ImmunoTherapy of Cancer 2020;8:e000966  (5 October 2020)
Review

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Matthias G Hautmann, Gunther Klautke, Simon Laban, Thomas Brunner, Axel Hinke, Ina Becker, Benjamin Frey, Sabine Semrau, Carol I Geppert, Arndt Hartmann, Panagiotis Balermpas, Wilfried Budach, Udo S Gaipl, Heinrich Iro, Rainer Fietkau
Journal for ImmunoTherapy of Cancer 2020;8:e001378  (6 October 2020)
Research

Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy

Ena Wang, Alessandra Cesano, Lisa H Butterfield, Francesco Marincola
Journal for ImmunoTherapy of Cancer 2020;8:e001619  (6 October 2020)
Commentary

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Zhen Zhang, Xinfeng Chen, Yonggui Tian, Feng Li, Xuan Zhao, Jinyan Liu, Chang Yao, Yi Zhang
Journal for ImmunoTherapy of Cancer 
2020;8:e001150  (6 October 2020)
Research

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

Linlin Shi, Jianyong Sheng, Guozhong Chen, Peng Zhu, Changping Shi, Bei Li, Chaiwoo Park, Jingyi Wang, Bixiang Zhang, Zhi Liu, Xiangliang Yang
Journal for ImmunoTherapy of Cancer 
2020;8:e000973 (7 October 2020)
Research

2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1

Zhanfei Chen, Yiyin Chen, Lirong Peng, Xiaoqian Wang, Nanhong Tang
Journal for ImmunoTherapy of Cancer 
2020;8:e001377 (7 October 2020)
Research

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy

Xuanwen Bao, Hangyu Zhang, Wei Wu, Shaobing Cheng, Xiaomeng Dai, Xudong Zhu, Qihan Fu, Zhou Tong, Lulu Liu, Yi Zheng, Peng Zhao, Weijia Fang, Fanglong Liu
Journal for ImmunoTherapy of Cancer 
2020;8:e001437 (7 October 2020)
Research

Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy

Zachary S Buchwald, Tahseen H Nasti, Judong Lee, Christiane S Eberhardt, Andres Wieland, Se Jin Im, David Lawson, Walter Curran, Rafi Ahmed, Mohammad K Khan
Journal for ImmunoTherapy of Cancer
 
2020;8:e000638  (7 October 2020)
Research

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma

Jeffrey C Thompson, Christiana Davis, Charuhas Deshpande, Wei-Ting Hwang, Seth Jeffries, Alexander Huang, Tara C Mitchell, Corey J Langer, Steven M Albelda
Journal for ImmunoTherapy of Cancer 2020;8:e000974  (7 October 2020)
Research

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

David J Pinato, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Uqba Khan, ChiehJu Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Petros Fessas, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Yi-Hsiang Huang, Jingky Lozano-Kuehne, Lorenza Rimassa, Celina Ang, Thomas U Marron
Journal for ImmunoTherapy of Cancer 2020;8:e000726 (7 October 2020)
Short Report

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis

Sienna M Durbin, Meghan J Mooradian, Florian Johannes Fintelmann, Leyre Zubiri, Donald F Chute, Avinash Kambadakone, Nisanard Pisuchpen, Kerry L Reynolds, Michael Dougan
Journal for ImmunoTherapy of Cancer 2020;8:e001329  (8 October 2020)
Research

Impact of age on the toxicity of immune checkpoint inhibition

Amit Samani, Shuai Zhang, Laura Spiers, Ali Abdulnabi Mohamed, Sophie Merrick, Zayd Tippu, Miranda Payne, Guy Faust, Sophie Papa, Paul Fields, Mieke Van Hemelrijck, Debra H Josephs
Journal for ImmunoTherapy of Cancer 2020;8:e000871  (8 October 2020)
Short Report

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

Andrea B Apolo, John A Ellerton, Jeffrey R Infante, Manish Agrawal, Michael S Gordon, Raid Aljumaily, Theodore Gourdin, Luc Dirix, Keun-Wook Lee, Matthew H Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Juliane Manitz, Gregory Pennock, Mary Ruisi, James L Gulley, Manish R Patel
Journal for ImmunoTherapy of Cancer 
2020;8:e001246 (9 October 2020)
Research

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer

Mitchell W Braun, Haitham Abdelhakim, Meizhang Li, Stephen Hyter, Ziyan Pessetto, Devin C Koestler, Harsh B Pathak, Neil Dunavin, Andrew K Godwin
Journal for ImmunoTherapy of Cancer 
2020;8:e000706 (9 October 2020)
Research

KALRN mutations promote antitumor immunity and immunotherapy response in cancer

Mengyuan Li, Yuxiang Ma, You Zhong, Qian Liu, Canping Chen, Lei Qiang, Xiaosheng Wang
Journal for ImmunoTherapy of Cancer 2020;8:e000293 (9 October 2020)
Research

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Lillian Siu, Joshua Brody, Shilpa Gupta, Aurélien Marabelle, Antonio Jimeno, Pamela Munster, Juneko Grilley-Olson, Alain H Rook, Antoine Hollebecque, Rebecca K S Wong, James W Welsh, Yuling Wu, Christopher Morehouse, Oday Hamid, Farzana Walcott, Zachary A Cooper, Rakesh Kumar, Charles Ferté, David S Hong
Journal for ImmunoTherapy of Cancer 
2020;8:e001095 (9 October 2020)
Research

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination

Chung-Hsiung Huang, Chiung-Yi Huang, Hui-Min Ho, Ching-Hung Lee, Pang-Ti Lai, Suh-Chin Wu, Shih-Jen Liu, Ming-Hsi Huang
Journal for ImmunoTherapy of Cancer 
2020;8:e001022 (9 October 2020)
Research

Evolving impact of long-term survival results on metastatic melanoma treatment

Olivier Michielin, Michael B Atkins, Henry B Koon, Reinhard Dummer, Paolo Antonio Ascierto
Journal for ImmunoTherapy of Cancer 
2020;8:e000948 (9 October 2020)
Review

Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway

Kim M van Pul, Ronald J C L M Vuylsteke, Monique T A de Beijer, Rieneke van de Ven, M Petrousjka van den Tol, Hein B A C Stockmann, Tanja D de Gruijl
Journal for ImmunoTherapy of Cancer 
2020;8:e000761 (12 October 2020)
Research

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Albiruni RA Razak, James M Cleary, Victor Moreno, Michael Boyer, Emiliano Calvo Aller, William Edenfield, Jeanne Tie, R Donald Harvey, Annemie Rutten, Manish A Shah, Anthony J Olszanski, Dirk Jäger, Nehal Lakhani, David P Ryan, Erik Rasmussen, Gloria Juan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit, Dirk Nagorsen, Kyriakos P Papadopoulos
Journal for ImmunoTherapy of Cancer 
2020;8:e001006 (12 October 2020)
Research

Clinical landscape of oncolytic virus research in 2020

Nicholas Macedo, David M Miller, Rizwan Haq, Howard L Kaufman
Journal for ImmunoTherapy of Cancer 2020;8:e001486  (12 October 2020)
Review

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy

Chunwan Lu, John D Klement, Alyssa D Smith, Dafeng Yang, Jennifer L Waller, Darren D Browning, David H Munn, Kebin Liu
Journal for ImmunoTherapy of Cancer 2020;8:e001365  (13 October 2020)
Research

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

James Welsh, Hari Menon, Dawei Chen, Vivek Verma, Chad Tang, Mehmet Altan, Kenneth Hess, Patricia de Groot, Quynh-Nhu Nguyen, Rejani Varghese, Nathan I Comeaux, George Simon, Ferdinandos Skoulidis, Joe Y Chang, Vasiliki Papdimitrakopoulou, Steven H Lin, John V Heymach
Journal for ImmunoTherapy of Cancer 2020;8:e001001  (13 October 2020)
Research

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade

Pranjal Vaidya, Kaustav Bera, Pradnya D Patil, Amit Gupta, Prantesh Jain, Mehdi Alilou, Mohammadhadi Khorrami, Vamsidhar Velcheti, Anant Madabhushi
Journal for ImmunoTherapy of Cancer 2020;8:e001343  (13 October 2020)
Research

Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer

Yungang Wang, Yanxia Ding, Yijun Deng, Yu Zheng, Shengjun Wang
Journal for ImmunoTherapy of Cancer 
2020;8:e000609 (13 October 2020)
Review

Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors

Wu-Hu Zhang, Wen-Quan Wang, Xuan Han, He-Li Gao, Shuai-Shuai Xu, Shuo Li, Tian-Jiao Li, Hua-Xiang Xu, Hao Li, Long-Yun Ye, Xuan Lin, Chun-Tao Wu, Jiang Long, Xian-Jun Yu, Liang Liu
Journal for ImmunoTherapy of Cancer 2020;8:e001188  (14 October 2020)
Research

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

Yinwen Cheng, Caitlin D Lemke-Miltner, Wattawan Wongpattaraworakul, Zhaoming Wang, Carlos H F Chan, Aliasger K Salem, George J Weiner, Andrean L Simons
Journal for ImmunoTherapy of Cancer 2020;8:e000940  (15 October 2020)
Research

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma

Alison M Weppler, Andrew Pattison, Prachi Bhave, Paolo De Ieso, Jeanette Raleigh, Athena Hatzimihalis, Anthony J Gill, Shiva Balachander, Jason Callahan, Margaret Chua, George Au-Yeung, Grant A McArthur, Rodney J Hicks, Richard W Tothill, Shahneen Sandhu
Journal for ImmunoTherapy of Cancer 2020;8:e000700  (15 October 2020)
Research

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

Margaret Ottaviano, Marcello Curvietto, Pasquale Rescigno, Marianna Tortora, Giovannella Palmieri, Diana Giannarelli, Michele Aieta, Pasquale Assalone, Laura Attademo, Antonio Avallone, Francesco Bloise, Davide Bosso, Valentina Borzillo, Giuseppe Buono, Giuseppe Calderoni, Francesca Caputo, Giacomo Cartenì, Diletta Cavallero, Alessia Cavo, Fortunato Ciardiello, Raffaele Conca, Vincenza Conteduca, Stefano De Falco, Marco De Felice, Michelino De Laurentiis, Pietro De Placido, Sabino De Placido, Irene De Santo, Alfonso De Stefano, Carminia Maria Della Corte, Rossella Di Franco, Vincenzo Di Lauro, Antonietta Fabbrocini, Piera Federico, Lucia Festino, Pasqualina Giordano, Mario Giuliano, Cesare Gridelli, Antonio Maria Grimaldi, Michela Lia, Antonella Lucia Marretta, Valentina Massa, Alessia Mennitto, Sara Merler, Valeria Merz, Carlo Messina, Marco Messina, Monica Milano, Alessandro Marco Minisini, Vincenzo Montesarchio, Alessandro Morabito, Floriana Morgillo, Brigitta Mucci, Lucia Nappi, Fabiana Napolitano, Immacolata Paciolla, Martina Pagliuca, Giuseppe Palmieri, Sara Parola, Stefano Pepe, Angelica Petrillo, Francovito Piantedosi, Luisa Piccin, Fernanda Picozzi, Erica Pietroluongo, Sandro Pignata, Veronica Prati, Vittorio Riccio, Mario Rosanova, Alice Rossi, Anna Russo, Massimiliano Salati, Giuseppe Santabarbara, Andrea Sbrana, Ester Simeone, Antonia Silvestri, Massimiliano Spada, Paolo Tarantino, Paola Taveggia, Federica Tomei, Tortora Vincenzo, Dario Trapani, Claudia Trojanello, Vito Vanella, Sabrina Vari, Jole Ventriglia, Maria Grazia Vitale, Fabiana Vitiello, Caterina Vivaldi, Claudia von Arx, Francesca Zacchi, Ilaria Zampiva, Andrea Zivi, Bruno Daniele, Paolo Antonio Ascierto
Journal for ImmunoTherapy of Cancer 2020;8:e001154  (15 October 2020)
Research

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial

Yan Song, Ning Li, Qun Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou, Jing Huang
Journal for ImmunoTherapy of Cancer 2020;8:e001279  (15 October 2020)
Research

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy

Dimitrios C Ziogas, Frosso Kostantinou, Evangelos Cholongitas, Amalia Anastasopoulou, Panagiotis Diamantopoulos, John Haanen, Helen Gogas
Journal for ImmunoTherapy of Cancer 
2020;8:e000943  (16 October 2020)
Review

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck, Bart Neyns
Journal for ImmunoTherapy of Cancer 
2020;8:e001052 (16 October 2020)
Research

Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey

Nilasha Ghosh, Aidan Tirpack, Karmela K Chan, Anne R Bass
Journal for ImmunoTherapy of Cancer 
2020;8:e001550 (16 October 2020)
Research

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Michael Wang, Preetesh Jain, T Linda Chi, Sheree E Chen, Amy Heimberger, Shiao-Pei Weathers, Lianqing Zheng, Arati V Rao, John M Rossi
Journal for ImmunoTherapy of Cancer 
2020;8:e001114 (16 October 2020)
Case Report

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions

Jules Russick, Pierre-Emmanuel Joubert, Mélanie Gillard-Bocquet, Carine Torset, Maxime Meylan, Florent Petitprez, Marie-Agnes Dragon-Durey, Solenne Marmier, Aditi Varthaman, Nathalie Josseaume, Claire Germain, Jérémy Goc, Marie-Caroline Dieu-Nosjean, Pierre Validire, Ludovic Fournel, Laurence Zitvogel, Gabriela Bindea, Audrey Lupo, Diane Damotte, Marco Alifano, Isabelle Cremer
Journal for ImmunoTherapy of Cancer
 
2020;8:e000638  (16 October 2020)
Research

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

Michael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, John Barrett, Renier J Brentjens, Jill Brufsky, Jorge Cortes, Marcos De Lima, Stephen J Forman, Ephraim J Fuchs, Linda J Fukas, Steven D Gore, Mark R Litzow, Jeffrey S Miller, John M Pagel, Edmund K Waller, Martin S Tallman
Journal for ImmunoTherapy of Cancer 2020;8:e000810  (19 October 2020)
Guideline

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Tae Hee Hong, Hongui Cha, Joon Ho Shim, Boram Lee, Jongsuk Chung, Chung Lee, Nayoung K D Kim, Yoon-La Choi, Soohyun Hwang, Yoomi Lee, Sehhoon Park, Hyun Ae Jung, Ji-Yeon Kim, Yeon Hee Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Se-Hoon Lee, Woong-Yang Park
Journal for ImmunoTherapy of Cancer 2020;8:e001199 (19 October 2020)
Research

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >/= 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo, Emilio Bria, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Raffaele Giusti, Diego L Cortinovis, Maria R Migliorino, Annamaria Catino, Francesco Passiglia, Mariangela Torniai, Alessandro Morabito, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Diego Signorelli, Alain Gelibter, Mario Alberto Occhipinti, Francesca Rastelli, Rita Chiari, Danilo Rocco, Alessandro Inno, Michele De Tursi, Pietro Di Marino, Giovanni Mansueto, Federica Zoratto, Francesco Grossi, Marco Filetti, Pamela Pizzutilo, Marco Russano, Fabrizio Citarella, Luca Cantini, Giada Targato, Olga Nigro, Miriam G Ferrara, Sebastiano Buti, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Luigi Della Gravara, Fabrizio Tabbò, Serena Ricciardi, Alessandro De Toma, Alex Friedlaender, Fausto Petrelli, Alfredo Addeo, Giampiero Porzio, Corrado Ficorella
Journal for ImmunoTherapy of Cancer 2020;8:e001403  (19 October 2020)
Research

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy

Christianne Groeneveldt, Priscilla Kinderman, Diana J M van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana A M Mustafa, Rob C Hoeben, Sjoerd H van der Burg, Thorbald van Hall, Nadine van Montfoort
Journal for ImmunoTherapy of Cancer 2020;8:e001191  (20 October 2020)
Research

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer

Peixin Chen, Liping Zhang, Wei Zhang, Chenglong Sun, Chunyan Wu, Yayi He, Caicun Zhou
Journal for ImmunoTherapy of Cancer 
2020;8:e001391 (20 October 2020)
Research

Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients

Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, David Rafei-Shamsabadi, Ralf Gutzmer, Katharina Kaehler, Lucie Heinzerling, Jessica C Hassel, Valerie Glutsch, Judith Sirokay, Nora Schlecht, Albert Rübben, Thilo Gambichler, Kerstin Schatton, Claudia Pfoehler, Cindy Franklin, Patrick Terheyden, Sebastian Haferkamp, Peter Mohr, Lena Bischof, Elisabeth Livingstone, Lisa Zimmer, Michael Weichenthal, Dirk Schadendorf, Andreas Meiwes, Ulrike Keim, Claus Garbe, Jürgen Christian Becker, Selma Ugurel
Journal for ImmunoTherapy of Cancer 
2020;8:e000897 (22 October 2020)
Research

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

Daan P Hurkmans, Christina Jensen, Stijn L W Koolen, Joachim Aerts, Morten Asser Karsdal, Ron H J Mathijssen, Nicholas Willumsen
Journal for ImmunoTherapy of Cancer 2020;8:e001193 (22 October 2020)
Research

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy

Koji Nagaoka, Masataka Shirai, Kiyomi Taniguchi, Akihiro Hosoi, Changbo Sun, Yukari Kobayashi, Kazuhiro Maejima, Masashi Fujita, Hidewaki Nakagawa, Sachiyo Nomura, Kazuhiro Kakimi
Journal for ImmunoTherapy of Cancer 
2020;8:e001358 (22 October 2020)
Research

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory

Tito Mendoza, Ajay Sheshadri, Mehmet Altan, Kenneth Hess, Goldy George, Bettzy Stephen, Lilibeth Castillo, Enedelia Rodriguez, Jing Gong, Christine Peterson, Jordi Rodon Ahnert, Siqing Fu, Sarina A Piha-Paul, Shubham Pant, Ecaterina Dumbrava, Timonthy A Yap, Filip Janku, Apostolia M Tsimberidou, Vivek Subbiah, Daniel D Karp, Abdulrazzak Zarifa, Lacey M McQuinn, Charles Cleeland, David S Hong, Aung Naing
Journal for ImmunoTherapy of Cancer 
2020;8:e000931 (23 October 2020)
Research

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Jean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, Dmitriy Zamarin, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Wolfgang Jacob, Anna-Maria Jegg, Michael A Cannarile, Carl Watson, Galina Babitzki, Konstanty Korski, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Francesca Michielin, Randolph Christen, Dominik Rüttinger, Martin Weisser, Jean-Pierre Delord, Philippe Cassier
Journal for ImmunoTherapy of Cancer 
2020;8:e001153 (23 October 2020)
Research

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer

Dengbo Ji, Can Song, Yongheng Li, Jinhong Xia, Yanjing Wu, Jinying Jia, Xinxin Cui, Songmao Yu, Jin Gu
Journal for ImmunoTherapy of Cancer 
2020;8:e000826 (26 October 2020)
Research

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma

Hampartsoum B Barsoumian, Rishab Ramapriyan, Ahmed I Younes, Mauricio S Caetano, Hari Menon, Nathan I Comeaux, Taylor R Cushman, Jonathan E Schoenhals, Alexandra P Cadena, Timothy P Reilly, Dawei Chen, Fatemeh Masrorpour, Ailin Li, David S Hong, Adi Diab, Quynh-Nhu Nguyen, Isabella Glitza, Renata Ferrarotto, Stephen G Chun, Maria Angelica Cortez, James Welsh
Journal for ImmunoTherapy of Cancer 
2020;8:e000877 (26 October 2020)
Research

Endogenous HLA-DQ8-alpha-beta programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival

Peter Knopick, David Terman, Nathan Riha, Travis Alvine, Riley Larson, Cedric Badiou, Gerard Lina, John Ballantyne, David Bradley
Journal for ImmunoTherapy of Cancer 2020;8:e001493  (27 October 2020)
Research

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

Yaya Chu, Gaurav Nayyar, Nang Kham Su, Jeremy M Rosenblum, Patrick Soon-Shiong, John Lee, Jeffrey T Safrit, Matthew Barth, Dean Lee, Mitchell S Cairo
Journal for ImmunoTherapy of Cancer 2020;8:e001238  (27 October 2020)
Research

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy

Yixiao Zhang, Yuan Yao, Peng Chen, Yu Liu, Hao Zhang, He Liu, Yu Liu, Hong Xu, Xibao Tian, Zichu Wang, Peng Chu, Dongyu Zhao, Hongxu Liu, Chenlei Zhang, Shuyuan Chen, Yuhong Zhao, Caigang Liu, Yongliang Yang
Journal for ImmunoTherapy of Cancer 2020;8:e001247  (27 October 2020)
Research

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction

Wenzheng Xia, Hanbin Chen, Didi Chen, Yijia Ye, Congying Xie, Meng Hou
Journal for ImmunoTherapy of Cancer 2020;8:e001293  (28 October 2020)
Research

In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination

Giorgia Mandili, Claudia Curcio, Sara Bulfamante, Laura Follia, Giulio Ferrero, Emanuela Mazza, Moitza Principe, Francesca Cordero, Maria Antonietta Satolli, Rosella Spadi, Andrea Evangelista, Daniele Giordano, Duy Viet, Paola Cappello, Francesco Novelli
Journal for ImmunoTherapy of Cancer 
2020;8:e001071 (28 October 2020)
Research

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model

Claire C Baniel, Elizabeth G Sumiec, Jacquelyn A Hank, Amber M Bates, Amy K Erbe, Alexander A Pieper, Anna G Hoefges, Ravi B Patel, Alexander L Rakhmilevich, Zachary S Morris, Paul M Sondel
Journal for ImmunoTherapy of Cancer 2020;8:e001262  (28 October 2020)
Research

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Michael C Jensen, Richard G Ellenbogen, Jean S Campbell, Robert H Pierce, Eric C Holland, Venu G Pillarisetty, Courtney A Crane
Journal for ImmunoTherapy of Cancer 2020;8:e001356  (October 2020)
Research

Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma

Xiran He, Yang Du, Zhijie Wang, Xin Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Pei Zhang, Di Wang, Yanhua Tian, Jiefei Han, Kailun Fei, Hua Bai, Jie Tian, Jie Wang
Journal for ImmunoTherapy of Cancer 2020;8:e000807  (28 October 2020)
Research

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

Xiaoqiang Qi, Ming Yang, Lixin Ma, Madeline Sauer, Diego Avella, Jussuf T Kaifi, Jeffrey Bryan, Kun Cheng, Kevin F Staveley-O’Carroll, Eric T Kimchi, Guangfu Li
Journal for ImmunoTherapy of Cancer 2020;8:e001038  (28 October 2020)
Research

EBV-EBNA1 constructs an immunosuppressive microenvironment for nasopharyngeal carcinoma by promoting the chemoattraction of Treg cells

Shaofen Huo, Yunfan Luo, Rui Deng, Xiong Liu, Jie Wang, Lu Wang, Bao Zhang, Fan Wang, Juan Lu, Xiangping Li
Journal for ImmunoTherapy of Cancer 2020;8:e001588  (29 October 2020)
Research

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

Jennifer L Gardell, Lisa R Matsumoto, Harrison Chinn, Kole R DeGolier, Shannon A Kreuser, Brooke Prieskorn, Stephanie Balcaitis, Amira Davis, Richard G Ellenbogen, Courtney A Crane
Journal for ImmunoTherapy of Cancer 
2020;8:e001202  (29 October 2020)
Research

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

Sergio Rutella, Michael A Cannarile, Sacha Gnjatic, Bruno Gomes, Justin Guinney, Vaios Karanikas, Mohan Karkada, John M Kirkwood, Beatrix Kotlan, Giuseppe V Masucci, Els Meeusen, Anne Monette, Aung Naing, Vésteinn Thorsson, Nicholas Tschernia, Ena Wang, Daniel K Wells, Timothy L Wyant, Alessandra Cesano
Journal for ImmunoTherapy of Cancer 
2020;8:e001389 (30 October 2020)
Position Article

Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy

Agnieszka Beata Malczewski, Severine Navarro, Jermaine IG Coward, Natkunam Ketheesan
Journal for ImmunoTherapy of Cancer 
2020;8:e001383 (30 October 2020)
Research

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor

Boning Zhang, John Victor Napoleon, Xin Liu, Qian Luo, Madduri Srinivasarao, Philip S Low
Journal for ImmunoTherapy of Cancer 
2020;8:e000756 (30 October 2020)
Research

CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation

Anna Christina Dragon, Katharina Zimmermann, Thomas Nerreter, Deborah Sandfort, Julia Lahrberg, Stephan Klöß, Christina Kloth, Caroline Mangare, Agnes Bonifacius, Sabine Tischer-Zimmermann, Rainer Blasczyk, Britta Maecker-Kolhoff, Barbara Uchanska-Ziegler, Hinrich Abken, Axel Schambach, Michael Hudecek, Britta Eiz-Vesper
Journal for ImmunoTherapy of Cancer
 
2020;8:e000736  (30 October 2020)
Research

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy

Rafael Cubas, Zia Khan, Qian Gong, Marina Moskalenko, Huizhong Xiong, Qinglin Ou, Christine Pai, Ryan Rodriguez, Jeanne Cheung, Andrew C Chan
Journal for ImmunoTherapy of Cancer 2020;8:e001439  (30 October 2020)
Research

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of Fc-gamma-R interactions

David Bauché, Smita Mauze, Christina Kochel, Jeff Grein, Anandi Sawant, Yulia Zybina, Wendy Blumenschein, Peng Yang, Lakshmanan Annamalai, Jennifer H Yearley, Juha Punnonen, Edward P Bowman, Alissa Chackerian, Drake Laface
Journal for ImmunoTherapy of Cancer 2020;8:e001584 (30 October 2020)
Research

SITC Members Receive 50 Percent Submission Discount in 2020

*As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles accepted in 2020.